CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $76.29 Average Price Target from Analysts

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $76.29.

Several brokerages have weighed in on CRSP. Mizuho upped their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Royal Bank of Canada raised their target price on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a research report on Thursday, February 22nd. Wells Fargo & Company lifted their price objective on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Finally, Morgan Stanley lifted their price objective on shares of CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $53.91 on Monday. The company has a 50-day simple moving average of $70.57 and a 200-day simple moving average of $63.81. The firm has a market capitalization of $4.58 billion, a P/E ratio of -27.50 and a beta of 1.76. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. During the same period in the prior year, the company posted ($1.41) EPS. The firm’s quarterly revenue was up 3253.3% on a year-over-year basis. As a group, equities analysts forecast that CRISPR Therapeutics will post -6.24 earnings per share for the current year.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the completion of the sale, the general counsel now owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $80.36, for a total transaction of $1,607,200.00. Following the sale, the chief executive officer now directly owns 187,377 shares of the company’s stock, valued at approximately $15,057,615.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,913 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now directly owns 57,371 shares in the company, valued at $4,570,747.57. The disclosure for this sale can be found here. Insiders sold 133,992 shares of company stock worth $9,157,835 in the last quarter. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CRSP. CWM LLC lifted its position in shares of CRISPR Therapeutics by 80.7% during the 3rd quarter. CWM LLC now owns 582 shares of the company’s stock valued at $26,000 after acquiring an additional 260 shares during the period. Tradewinds Capital Management LLC lifted its holdings in shares of CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company’s stock worth $32,000 after buying an additional 600 shares in the last quarter. Blue Trust Inc. purchased a new stake in shares of CRISPR Therapeutics in the fourth quarter worth about $32,000. Headlands Technologies LLC purchased a new stake in shares of CRISPR Therapeutics in the third quarter worth about $34,000. Finally, Bourgeon Capital Management LLC raised its stake in CRISPR Therapeutics by 1,000.0% in the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock valued at $34,000 after purchasing an additional 500 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.